Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations
Martin Reck, Geetha Shankar, Anthony Lee et al. · Expert Review of Respiratory Medicine · 2019
Introduction: Cancer immunotherapy has revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC). However, specific patient groups (e.g. patients with activating epidermal growth factor receptor [EGFR] mutations) do not appear to derive benefit from immune checkpoint inhibitor (ICI) monotherapy. Combining ICIs, such as atezolizumab, with chemotherapy and/or targeted therapies may help to address this unmet need.Areas covered: Atezolizumab is an anti–programmed death-ligand 1 therapy for several tumor types. We review its clinical efficacy and safety in the treatment of advanced or metastatic NSCLC, with a specific focus on the combination of atezolizumab with bevacizumab, carboplatin, and paclitaxel (ABCP). Data from IMpower150 show that the ABCP regimen provided clinical benefit to patients with non-squamous NSCLC, including those with EGFR mutations.Expert opinion: Combining ICIs with chemotherapy has proven to be superior to chemotherapy alone. However, tumor resistance to ICIs will likely increase as these drugs enter earlier lines of therapy, underscoring a need for effective treatments when immunotherapy fails. Data suggest that the ABCP regimen may circumvent ICI resistance mechanisms. Continued investigation into the regimen’s mechanisms, improved patient profiling/selection, and treatment personalization will drive further development/discoveries.
Cited by 62 works. doi:10.1080/17476348.2020.1701439
Authors
- Martin Reck
- Geetha Shankar
- Shelley Coleman
- Mark L. McCleland
- Vassiliki A. Papadimitrakopoulou
- Mark A. Socinski
- Alan Sandler
References
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- Hallmarks of Cancer: The Next Generation
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Targeting HIF-1 for cancer therapy
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer